Dolutegravir Sodium; Rilpivirine Hydrochloride Patent Expiration
Dolutegravir Sodium; Rilpivirine Hydrochloride is Used for managing HIV infection. It was first introduced by Viiv Healthcare Co
Dolutegravir Sodium; Rilpivirine Hydrochloride Patents
Given below is the list of patents protecting Dolutegravir Sodium; Rilpivirine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Juluca | US12011506 | Combination and uses and treatments thereof | Sep 05, 2038 | Viiv Hlthcare |
| Juluca | US10426780 | Antiviral therapy | Jan 24, 2031 | Viiv Hlthcare |
| Juluca |
US9242986 (Pediatric) | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Jun 08, 2030 | Viiv Hlthcare |
| Juluca | US9242986 | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates | Dec 08, 2029 | Viiv Hlthcare |
| Juluca |
US8129385 (Pediatric) | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Apr 05, 2028 | Viiv Hlthcare |
| Juluca | US8129385 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | Oct 05, 2027 | Viiv Hlthcare |
| Juluca | US7125879 | HIV inhibiting pyrimidines derivatives | Apr 21, 2025 | Viiv Hlthcare |
| Juluca | US8080551 | HIV inhibiting pyrimidines derivatives |
Apr 11, 2023
(Expired) | Viiv Hlthcare |
| Juluca | US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug 09, 2022
(Expired) | Viiv Hlthcare |
| Juluca | US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb 26, 2021
(Expired) | Viiv Hlthcare |
| Juluca | US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec 20, 2019
(Expired) | Viiv Hlthcare |
Dolutegravir Sodium; Rilpivirine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List